Intraday Info: OpGen Inc (NASDAQ:OPGN) locked on 08/02/2017 at $1.12. It has average volume 746,630 whilst it totals volume 186,896. The company has EPS -1.30 and according to analysts next quarter EPS and next year estimate EPS will -0.19 and -0.52 respectively.
Ownership Summary: OpGen Inc has total institutional ownership 14.40% while its total outstanding shares 22 millions that’s value of holdings $3 million.
Active Positions: In the latest year, OPGN 6 holders have raised its positions while it contains total 1,378,674 shares. And the strength of reduced positions holders and held positions holders are 7 and 2 respectively.
New and Sold Out Positions: In OPGN force of new positions holders 2 and it has total shares 839,145. And force of sold out positions holders 4 and it has 112,274 shares.
Comparison with Other Company: The Market Value of OPGN is $24,540 below from Cigna Corporation market value which is $37M. Current Last Sale of OPGN is $1.13 below from CI current last sale which is $147.84.
OpGen, Inc. offers a portfolio of in vitro diagnostic products and clinical laboratory services that appoint molecular diagnostics and bioinformatics. Its QuickFISH merchandise are a collection of FDA-cleared and CE-marked diagnostics used to stumble on pathogens in advantageous blood cultures. The organisation affords Acuitas MDRO gene take a look at to identify the presence of antibiotic resistant genes for high-threat patients quickly and with high sensitivity and specificity; and Acuitas Lighthouse MDRO administration machine, which offers epidemiological typing, monitoring, and trending to inform infection control, surveillance, and antibiotic stewardship decision makers.
Further, it gives Acuitas entire genome sequence evaluation for transmission investigations and epidemiology research. OpGen, Inc. has a deliberate partnershipwith Hitachi high-technology organisation to commercialize its genome mapping generation for mapping, meeting, and analysis of human DNA.